SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-18-004623
Filing Date
2018-01-05
Accepted
2018-01-05 17:21:33
Documents
4
Period of Report
2018-01-04
Items
Item 3.03: Material Modifications to Rights of Security Holders
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d521436d8k.htm 8-K 21353
2 EX-3.1 d521436dex31.htm EX-3.1 8271
3 EX-99.1 d521436dex991.htm EX-99.1 12496
4 GRAPHIC g521436g0105090302667.jpg GRAPHIC 3736
  Complete submission text file 0001193125-18-004623.txt   48701
Mailing Address 257 SIMARANO DRIVE SUITE 101 MARLBOROUGH MA 01752
Business Address 257 SIMARANO DRIVE SUITE 101 MARLBOROUGH MA 01752 (508) 767-3861
RXi Pharmaceuticals Corp (Filer) CIK: 0001533040 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36304 | Film No.: 18514247
SIC: 2834 Pharmaceutical Preparations